Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
Yang Liu(Fox Chase Cancer Center), Stefan K. Barta(University of Pennsylvania)
Cited by 503
Related Papers
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
|Nature Medicine|2024|254
Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas
|Annals of Oncology|2022|95
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study
|Journal of Hematology & Oncology|2023|52